GlassScriptPhysician profile
Marc Mccleary
NPI 1790770584
$1,746.30
in general payments reported to CMS, 2019-2025
19 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.54 · 2020: $118 · 2021: $414 · 2022: $212 · 2023: $155 · 2024: $194 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $329.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $309.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $239.33 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $169.95 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.58 | 2021-2022 | |
| Amgen INC. | $94.55 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $82.88 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $59.95 | 2025 | Rexulti |
| Amarin Pharma, INC. | $55.67 | 2019-2021 | |
| Abbvie INC. | $49.13 | 2021-2025 | |
| Dexcom, INC. | $43.02 | 2021-2022 | |
| Astellas Pharma US INC | $39.39 | 2020-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $36.22 | 2022 | |
| Pfizer INC. | $35.29 | 2019-2023 | |
| Dynavax Technologies Corporation | $16.01 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.39 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.76 | 2021 | |
| Electromed, INC. | $11.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Mccleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.